Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis, and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an FXR agonist and an SSAO inhibitor.

The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.

The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using specific FXR agonists, in particular for treating or preventing liver diseases.

A composition for treating a burn wound, containing a variety of ingredients, including a fatty acid 261-639 mg, an organic substance 3.5-350 mg, a carbohydrate 0.02-60 mg, a vitamin 9-13 μg, a microelement 3.04-5.5 mg, an antibiotic 0.6-70 mg, and an amino acid 105-335 mg. The significant therapeutic effects include effectively promoting repair of a burn wound, anti-infection, inhibiting scar hyperplasia, no toxic side effect, convenient use, fast absorption, economical efficiency, etc. The composition provides patients with an efficient, economical, convenient and practical treatment for burn wounds, which greatly reduces the burden on patients, and effectively compensates for the various deficiencies of the current treatments for the non-healing burn wounds.

A composition for treating a burn wound, containing a variety of ingredients, including a fatty acid 261-639 mg, an organic substance 3.5-350 mg, a carbohydrate 0.02-60 mg, a vitamin 9-13 μg, a microelement 3.04-5.5 mg, an antibiotic 0.6-70 mg, and an amino acid 105-335 mg. The significant therapeutic effects include effectively promoting repair of a burn wound, anti-infection, inhibiting scar hyperplasia, no toxic side effect, convenient use, fast absorption, economical efficiency, etc. The composition provides patients with an efficient, economical, convenient and practical treatment for burn wounds, which greatly reduces the burden on patients, and effectively compensates for the various deficiencies of the current treatments for the non-healing burn wounds.

The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R.sup.1, R.sup.2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.

##STR00001##

The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R.sup.1, R.sup.2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.

##STR00001##

Articles, systems, and methods for rapid administration and active pharmaceutical compositions to subjects exposed to radiation and/or toxins are provided by this disclosure. There are currently few interventional technologies to protect against long-term morbidity and mortality from exposure to radiation and chemical warfare. Furthermore, as commercially available technologies such as additive manufacturing and small-scale chemical reactors have become more prevalent, the risk of misuse of such technologies by terrorists and rogue nation states to manufacture nuclear, radiologic, and chemical weapons continues to increase. Articles, systems, and methods described herein combine sensing technologies with drug release components, in order to provide an approach for rapid diagnosis of and response to exposure to radiation and toxic agents.

Articles, systems, and methods for rapid administration and active pharmaceutical compositions to subjects exposed to radiation and/or toxins are provided by this disclosure. There are currently few interventional technologies to protect against long-term morbidity and mortality from exposure to radiation and chemical warfare. Furthermore, as commercially available technologies such as additive manufacturing and small-scale chemical reactors have become more prevalent, the risk of misuse of such technologies by terrorists and rogue nation states to manufacture nuclear, radiologic, and chemical weapons continues to increase. Articles, systems, and methods described herein combine sensing technologies with drug release components, in order to provide an approach for rapid diagnosis of and response to exposure to radiation and toxic agents.